Pfizer's ELREXFIOTM Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
ELREXFIO is the first off‐the‐shelf (ready‐to‐use) fixed‐dose subcutaneous BCMA‐directed agent in the U.S. with the option for every‐other‐week long‐term dosing after 24 weeks of weekly treatment.
